Literature DB >> 28218824

Decreased home cage movement and oromotor impairments in adult Fmr1-KO mice.

S J Bonasera1, T R Chaudoin1, E H Goulding2, M Mittek3, A Dunaevsky4.   

Abstract

Fragile X syndrome (FXS) is a common inherited disorder that significantly impacts family and patient day-to-day living across the entire life span. The childhood and adolescent behavioral consequences of FXS are well appreciated. However, there are significantly fewer studies (except those examining psychiatric comorbidities) assessing behavioral phenotypes seen in adults with FXS. Mice engineered with a genetic lesion of fragile X mental retardation 1 (Fmr1) recapitulate important molecular and neuroanatomical characteristics of FXS, and provide a means to evaluate adult behavioral phenotypes associated with FXS. We give the first description of baseline behaviors including feeding, drinking, movement and their circadian rhythms; all observed over 16 consecutive days following extensive environmental habituation in adult Fmr1-KO mutant mice. We find no genotypic changes in mouse food ingestion, feeding patterns, metabolism or circadian patterns of movement, feeding and drinking. After habituation, Fmr1-KO mice show significantly less daily movement during their active phase (the dark cycle). However, Fmr1-KO mice have more bouts of activity during the light cycle compared with wild types. In addition, Fmr1-KO mice show significantly less daily water ingestion during the circadian dark cycle, and this reduction in water intake is accompanied by a decrease in the amount of water ingested per lick. The observed water ingestion and circadian phenotypes noted in Fmr1-KO mice recapitulate known clinical aspects previously described in FXS. The finding of decreased movement in Fmr1-KO mice is novel, and suggests a dissociation between baseline and novelty-evoked activity for Fmr1-KO mice.
© 2017 John Wiley & Sons Ltd and International Behavioural and Neural Genetics Society.

Entities:  

Keywords:  Fmr1-KO mouse; behavior; fragile X syndrome; home cage; locomotion; water ingestion

Mesh:

Substances:

Year:  2017        PMID: 28218824      PMCID: PMC6042514          DOI: 10.1111/gbb.12374

Source DB:  PubMed          Journal:  Genes Brain Behav        ISSN: 1601-183X            Impact factor:   3.449


  71 in total

1.  A null mutation for Fmr1 in female mice: effects on regional cerebral metabolic rate for glucose and relationship to behavior.

Authors:  M Qin; J Kang; C Beebe Smith
Journal:  Neuroscience       Date:  2005-09-08       Impact factor: 3.590

2.  Comprehensive motor testing in Fmr1-KO mice exposes temporal defects in oromotor coordination.

Authors:  Snigdha Roy; Yu Zhao; Melody Allensworth; Mohamed F Farook; Mark S LeDoux; Lawrence T Reiter; Detlef H Heck
Journal:  Behav Neurosci       Date:  2011-10-17       Impact factor: 1.912

3.  Medication utilization for targeted symptoms in children and adults with fragile X syndrome: US survey.

Authors:  Donald B Bailey; Melissa Raspa; Ellen Bishop; Murrey Olmsted; Usha G Mallya; Elizabeth Berry-Kravis
Journal:  J Dev Behav Pediatr       Date:  2012-01       Impact factor: 2.225

4.  Mildly impaired water maze performance in male Fmr1 knockout mice.

Authors:  R D'Hooge; G Nagels; F Franck; C E Bakker; E Reyniers; K Storm; R F Kooy; B A Oostra; P J Willems; P P De Deyn
Journal:  Neuroscience       Date:  1997-01       Impact factor: 3.590

5.  Behavioral and neuroanatomical characterization of the Fmr1 knockout mouse.

Authors:  Yann S Mineur; Frans Sluyter; Sanne de Wit; Ben A Oostra; Wim E Crusio
Journal:  Hippocampus       Date:  2002       Impact factor: 3.899

6.  A guide to analysis of mouse energy metabolism.

Authors:  Matthias H Tschöp; John R Speakman; Jonathan R S Arch; Johan Auwerx; Jens C Brüning; Lawrence Chan; Robert H Eckel; Robert V Farese; Jose E Galgani; Catherine Hambly; Mark A Herman; Tamas L Horvath; Barbara B Kahn; Sara C Kozma; Eleftheria Maratos-Flier; Timo D Müller; Heike Münzberg; Paul T Pfluger; Leona Plum; Marc L Reitman; Kamal Rahmouni; Gerald I Shulman; George Thomas; C Ronald Kahn; Eric Ravussin
Journal:  Nat Methods       Date:  2011-12-28       Impact factor: 28.547

7.  Anatomical phenotyping in a mouse model of fragile X syndrome with magnetic resonance imaging.

Authors:  Jacob Ellegood; Laura K Pacey; David R Hampson; Jason P Lerch; R Mark Henkelman
Journal:  Neuroimage       Date:  2010-03-19       Impact factor: 6.556

8.  Psychiatric and autistic comorbidity in fragile X syndrome across ages.

Authors:  Lidia V Gabis; Yael Kesner Baruch; Ariela Jokel; Raanan Raz
Journal:  J Child Neurol       Date:  2011-04-27       Impact factor: 1.987

Review 9.  Fragile X spectrum disorders.

Authors:  Reymundo Lozano; Carolina Alba Rosero; Randi J Hagerman
Journal:  Intractable Rare Dis Res       Date:  2014-11

10.  Autistic-like behaviour profile and psychiatric morbidity in Fragile X Syndrome: a prospective ten-year follow-up study.

Authors:  Manga Sabaratnam; Naga Venkatesha Murthy; Anusha Wijeratne; Ann Buckingham; Stewart Payne
Journal:  Eur Child Adolesc Psychiatry       Date:  2003-08       Impact factor: 4.785

View more
  4 in total

1.  Home-cage hypoactivity in mouse genetic models of autism spectrum disorder.

Authors:  Christopher C Angelakos; Jennifer C Tudor; Sarah L Ferri; Thomas A Jongens; Ted Abel
Journal:  Neurobiol Learn Mem       Date:  2019-02-20       Impact factor: 3.109

2.  Home-cage monitoring ascertains signatures of ictal and interictal behavior in mouse models of generalized seizures.

Authors:  Miranda J Jankovic; Paarth P Kapadia; Vaishnav Krishnan
Journal:  PLoS One       Date:  2019-11-07       Impact factor: 3.240

3.  Toll-Like Receptor 2 Is a Regulator of Circadian Active and Inactive State Consolidation in C57BL/6 Mice.

Authors:  Nicholas W DeKorver; Tammy R Chaudoin; Stephen J Bonasera
Journal:  Front Aging Neurosci       Date:  2017-07-14       Impact factor: 5.750

4.  Mice lacking galectin-3 (Lgals3) function have decreased home cage movement.

Authors:  Tammy R Chaudoin; Stephen J Bonasera
Journal:  BMC Neurosci       Date:  2018-05-02       Impact factor: 3.288

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.